Bavarian Nordic A/S: Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic to initiate Phase 3 with RSV vaccine candidate in first half of 2022 subject to a successful equity capital raiseEBITDA expectations for 2021 slightly lowered, as Phase 3 preparations are

Related Keywords

United States ,Canada ,Denmark ,Copenhagen ,Køavn ,United Kingdom ,Paul Chaplin ,Graham Morrell ,Janssen Pharmaceutical Companies Of Johnson ,Nordea ,Company Announcement ,Bavarian Nordic ,Respiratory Syncytial Virus ,Janssen Pharmaceutical Companies ,Joint Global Coordinators ,Joint Bookrunners ,Vice President Investor Relations ,Paddock Circle Advisors ,Bavarian ,Ordic ,Commits ,Initiating ,Hase ,Trial ,Vaccine ,Candidate ,Strengthening ,Capital ,